Dong-A Socio Group said on the 17th it will attend Bio USA (BIO International Convention) 2026, to be held June 22–25 (local time) in San Diego, and move to expand partnerships.
Bio USA, hosted by the Biotechnology Innovation Organization, is the world's largest pharmaceutical and biotech event, drawing more than 20,000 participants from about 70 countries. Discussions include introductions to research and development (R&D) results and pipelines, technology licensing, investment attraction, and business collaboration.
At this event, Dong-A ST, a new drug development corporations under Dong-A Socio Group, ST Pharm, an integrated RNA therapeutic contract development and manufacturing organizations (CDMO) corporations, and BTGEN, a biopharmaceutical contract manufacturing organizations (CMO) corporations, will run a joint booth. Oh Yun-seok, executive vice president and head of R&D at Dong-A ST, Seong Mu-je, president of ST Pharm, and Lee Hyun-min, president of BTGEN, will also be on site to meet directly with global clients and partners.
Dong-A ST will introduce its innovative new drug pipeline in oncology, immuno-inflammation, and neurodegenerative diseases, as well as its biosimilar business. While seeking opportunities for technology licensing and joint development with global pharmaceutical and biotech companies, it also plans to carry out open innovation activities, reviewing the potential introduction of assets from the early research stage to the clinical stage.
ST Pharm will showcase its oligonucleotide therapeutic manufacturing capabilities based on the operation of its second oligo facility. Oligonucleotide therapeutics are next-generation RNA therapies that regulate gene expression to treat diseases. The company will present its manufacturing and quality control systems that can handle everything from early clinical quantities to mass production after commercialization, and will highlight mRNA-based therapeutic CDMO competitiveness with its proprietary 5′ capping technology, "SmartCap®," and its lipid nanoparticle (LNP) formulation technology, "STLNP®."
BTGEN recently expanded its first plant, increasing its biopharmaceutical production capabilities. The bioreactor scale grew from 9,000 liters to 14,000 liters, and production culture capacity also rose by about 55%. The company plans to emphasize that it is securing growth drivers through a "Dual Track" strategy that simultaneously advances rare disease therapeutic development and a biosimilar business replicating biopharmaceuticals whose patents have expired.
A group representative said, "We will introduce the group's capabilities spanning new drug development, RNA therapeutic CDMO, and biopharmaceutical CMO to the global market," adding, "We will expand opportunities for business collaboration through meetings with clients and potential clients."